Advanced Medical Solutions GroupCHIX:AMSL -0.36%93 Peter Lynch Fair Value is £1.56 as of Jul. 09, 2026, which is 100% below its 10-year median of 2.07. GuruFocus rates CHIX:AMSL with a GF Score™ of 93/100 and a GF Value™ of £3.72 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 154 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks worse than 58.44% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
The historical rank and industry rank for Advanced Medical Solutions Group's Peter Lynch Fair Value or its related term are showing as below:
CHIX:AMSl'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.4 Med: 2.07 Max: 3.66
Current: 1.79
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Advanced Medical Solutions Group was 3.66. The lowest was 1.40. And the median was 2.07.
CHIX:AMSl's Price-to-Peter-Lynch-Fair-Value is ranked worse than 58.44% of 154
companies
in the Medical Devices & Instruments industry
Industry Median: 1.5
vs CHIX:AMSl: 1.79
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Advanced Medical Solutions Group (CHIX:AMSl) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 13.35 instead of 15 in this case.
Advanced Medical Solutions Group's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
2.7875
/
1.56
=
1.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group Peter Lynch Fair Value Related Terms
Advanced Medical Solutions Group Peter Lynch Fair Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group Peter Lynch Fair Value Chart
CHIX:AMSL vs ISRG, BDX, MDLN: Peter Lynch Fair Value Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group Price-to-Peter-Lynch-Fair-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Medical Solutions Group's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was £0.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
Advanced Medical Solutions Group (CHIX:AMSL) has a Peter Lynch Fair Value of £1.56 as of Jul. 09, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Advanced Medical Solutions Group and its competitors. This is 25% below median its historical median of 2.07. Over the past decade, Advanced Medical Solutions Group's Peter Lynch Fair Value has ranged from 1.40 to 3.66. According to the industry distribution chart, Advanced Medical Solutions Group ranks #90 out of 154 companies in the Medical Devices & Instruments industry, placing it in the top 58.4%.
Is Advanced Medical Solutions Group's Peter Lynch Fair Value too high?
Advanced Medical Solutions Group's current Peter Lynch Fair Value of £1.56 is 25% below median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 3.66. Based on the distribution chart, Advanced Medical Solutions Group ranks #90 out of 154 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Advanced Medical Solutions Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Peter Lynch Fair Value compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #90 out of 154 companies for Peter Lynch Fair Value. This places Advanced Medical Solutions Group in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.50. Historically, Advanced Medical Solutions Group's own Peter Lynch Fair Value has ranged from 1.40 to 3.66 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Devices & Instruments company?
The median Peter Lynch Fair Value among Medical Devices & Instruments companies is 1.50, based on 154 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Advanced Medical Solutions Group and its competitors. For the Medical Devices & Instruments industry, the median Peter Lynch Fair Value is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current Peter Lynch Fair Value is £1.56, which is 25% below median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.72, compared to a current price of £2.79 — trading 25.1% below its estimated fair value. The current Peter Lynch Fair Value is £1.56, which is 25% below median its 10-year median of 2.07. Advanced Medical Solutions Group's overall GF Score™ is 93/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current Peter Lynch Fair Value is £1.56 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.79 is trading 25.1% below its estimated GF Value™ of £3.72.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
Peter Lynch Fair Value: £1.56 (25% below median its 10-year median of 2.07)
GF Value™: £3.72 vs. price of £2.79 (25.1% below fair value)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group Business Description
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
93GF Score
Get the complete analysis for CHIX:AMSL
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 
